From October 1, 2022 to December 31, 2022, the company has repurchased 0 shares, representing 0% for ?0 million. With this, the company has completed the repurchase of 2,052,808 shares, representing 3.72% for ?135.01 million under the buyback announced on November 3, 2021.
Market Closed -
Other stock markets
|
After market 20:54:40 | |||
85.5 EUR | +0.65% |
|
85.68 | +0.20% |
06-26 | Rovi receives non-binding offers for manufacturing business | RE |
05-08 | Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+42.03% | 4.76B | |
+56.94% | 809B | |
+39.52% | 624B | |
-6.74% | 351B | |
+7.48% | 289B | |
+13.74% | 240B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.84% | 166B | |
-2.73% | 157B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.